Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 4 of 4
Full-Text Articles in Psychology
Asenapine Sensitization From Adolescence To Adulthood And Its Potential Molecular Basis, Qing Shu, Rongyin Qin, Yingzhu Chen, Gang Hu, Ming Li
Asenapine Sensitization From Adolescence To Adulthood And Its Potential Molecular Basis, Qing Shu, Rongyin Qin, Yingzhu Chen, Gang Hu, Ming Li
Department of Psychology: Faculty Publications
Asenapine is a new antipsychotic drug that induces a long-lasting behavioral sensitization in adult rats. The present study investigated the developmental impacts of adolescent asenapine treatment on drug sensitivity and on 3 proteins implicated in the action of antipsychotic drugs (i.e. Brainderived neurotrophic factor (BDNF), dopamine D2 receptor, and ΔFosB) in adulthood. Male adolescent Sprague-Dawley rats (postnatal days, P 43-48) were first treated with asenapine (0.05, 0.10 or 0.20 mg/kg, sc) and tested in the conditioned avoidance or PCP (2.0 mg/kg, sc)-induced hyperlocomotion tasks for 5 days. After they became adults (∼P 76), asenapine sensitization was assessed in a …
Effect Of Environmental Cues On Behavioral Efficacy Of Haloperidol, Olanzapine And Clozapine In Rats, Tao Sun, Xinfeng Liu, Ming Li
Effect Of Environmental Cues On Behavioral Efficacy Of Haloperidol, Olanzapine And Clozapine In Rats, Tao Sun, Xinfeng Liu, Ming Li
Department of Psychology: Faculty Publications
Previous studies have reported that context can powerfully modulate the inhibitory effect of an antipsychotic drug on phencyclidine (PCP)-induced hyperlocomotion (a behavioral test used to evaluate putative antipsychotic drugs). The present study investigated the experimental conditions under which environmental stimuli exert their influence through associative conditioning processes. Experiment 1 examined the extent to which prior antipsychotic treatment in the home cages affected a drug’s ability to inhibit PCP-induced hyperlocomotion in a novel motor activity test apparatus. Five days of repeated haloperidol (0.05 mg/kg, sc) and olanzapine (2.0 mg/kg, sc) treatment in the home cages still potentiated their inhibition of PCP-induced …
Repeated Asenapine Treatment Produces A Sensitization Effect In Two Preclinical Tests Of Antipsychotic Activity, Rongyin Qin, Yingzhu Chen, Ming Li
Repeated Asenapine Treatment Produces A Sensitization Effect In Two Preclinical Tests Of Antipsychotic Activity, Rongyin Qin, Yingzhu Chen, Ming Li
Department of Psychology: Faculty Publications
Among several commonly used atypical antipsychotic drugs, olanzapine and risperidone cause a sensitization effect in the conditioned avoidance response (CAR) and phencyclidine (PCP)- induced hyperlocomotion paradigms – two well established animal tests of antipsychotic drugs, whereas clozapine causes a tolerance effect. Asenapine is a novel antipsychotic drug recently approved for the treatment of schizophrenia and manic disorders. It shares several receptor binding sites and behavioral features with other atypical antipsychotic drugs. However, it is not clear what type of repeated effect (sensitization or tolerance) asenapine would induce, and whether such an effect is transferrable to other atypicals. In this study, …
Iptakalim Preferentially Decreases Nicotine-Induced Hyperlocomotion In Phencyclidine-Sensitized Rats: A Potential Dual Action Against Nicotine Addiction And Psychosis, Nick Volf, Gang Hu, Ming Li
Iptakalim Preferentially Decreases Nicotine-Induced Hyperlocomotion In Phencyclidine-Sensitized Rats: A Potential Dual Action Against Nicotine Addiction And Psychosis, Nick Volf, Gang Hu, Ming Li
Department of Psychology: Faculty Publications
Objective: Iptakalim is a putative ATP-sensitive potassium (KATP) channel opener. It is also a novel nicotinic acetylcholine receptor (nAChR) blocker and can antagonize nicotine-induced increase in dopamine release in the nucleus accumbens. Our recent work also shows that iptakalim exhibits a clozapine-like atypical antipsychotic profile, indicating that iptakalim may possess a dual action against nicotine addiction and schizophrenia.
Methods: The present study examined the potential therapeutic effects of iptakalim on nicotine use in schizophrenia. We created an animal model of comorbidity of nicotine addiction and schizophrenia by injecting male Sprague-Dawley rats with nicotine (0.40 mg/kg, subcutaneously[sc]) or saline, in combination …